| dc.contributor.author | Leiter, Lawrence A. | |
| dc.contributor.author | Satman, Ilhan | |
| dc.contributor.author | Shestakova, Marina V. | |
| dc.date.accessioned | 2021-03-03T18:12:55Z | |
| dc.date.available | 2021-03-03T18:12:55Z | |
| dc.identifier.citation | Leiter L. A. , Shestakova M. V. , Satman I., "Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial", DIABETOLOGY & METABOLIC SYNDROME, cilt.10, 2018 | |
| dc.identifier.issn | 1758-5996 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_4dd5310f-2be9-4b83-8f8c-823aaf16773d | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/55623 | |
| dc.identifier.uri | https://doi.org/10.1186/s13098-018-0331-8 | |
| dc.description.abstract | Background: Although the number of antihyperglycemic agents has expanded significantly, sulfonylureas (in particular gliclazide) remain an important option because of a variety of patient and health system factors. The large, real world, observational, and international EASYDia trial evaluated the effectiveness of gliclazide modified release (MR) 60 mg in individuals with type 2 diabetes with a broad range of diabetes history, body mass index (BMI) and background antihyperglycemic treatment. | |
| dc.language.iso | eng | |
| dc.subject | Endokrinoloji ve Metabolizma Hastalıkları | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Tıp | |
| dc.subject | Klinik Tıp (MED) | |
| dc.subject | Klinik Tıp | |
| dc.subject | ENDOKRİNOLOJİ VE METABOLİZMA | |
| dc.title | Effectiveness of gliclazide MR 60 mg in the management of type 2 diabetes: analyses from the EASYDia trial | |
| dc.type | Makale | |
| dc.relation.journal | DIABETOLOGY & METABOLIC SYNDROME | |
| dc.contributor.department | University Of Toronto , , | |
| dc.identifier.volume | 10 | |
| dc.contributor.firstauthorID | 252589 | |
